A meta-analysis by Scirocchi showed that high levels of sPD-L1 correlated with shorter OS and PFS in patients with different types of cancer treated with immunotherapy (HR = 1.49, 95% CI 1.15–1.93, p < 0.01; OS: HR = 1.59, 95% CI 1.20–2.12, p < 0.01, for PFS). The gene discussed is SPDL1; the disease is cancer.